HOME >> MEDICINE >> NEWS
Rice bioengineer wins ASME's Van C. Mow Medal

HOUSTON, June 20, 2005 Renowned Rice University bioengineer Kyriacos Athanasiou has been awarded the inaugural Van. C. Mow Medal from the American Society of Mechanical Engineers.

Athanasiou, the Karl F. Hasselmann Professor of Bioengineering, was selected "for pioneering work in articular cartilage bioengineering, particularly the invention of a self-assembling approach without use of scaffolds to engineer articular cartilage constructs with properties approaching those of native cartilage."

Established in 2004, the Van C. Mow Medal is given annually to an individual who has made significant contributions to the field of bioengineering through research, education, professional development, leadership in the development of the profession, as a mentor to young investigators and with service to the bioengineering community.

"Having known and studied under Van Mow at Columbia, I am extremely honored to receive this inaugural award from ASME," said Athanasiou. "Dr. Mow embodied each of the characteristics this award honors, and it is humbling to be mentioned in such esteemed company."

A past president of the Biomedical Engineering Society (BMES), Athanasiou was elected to the society's inaugural class of fellows in April. The society, an international professional organization representing more than 3,000 bioengineers and biomedical engineers, is the lead society for the accreditation of bioengineering and biomedical engineering departments in the United States. In addition to serving as BMES president in 2003-2004, Athanasiou is a past member of its board of directors and a past chair of both its finance and membership committees. Athanasiou currently serves on the society's executive committee and also serves as faculty adviser to Rice's student chapter of BMES.

Athanasiou has published more than 150 peer-reviewed papers, 200 conference proceedings and abstracts, and he holds some 25 U.S. patents. He has mentored mo
'"/>

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University
20-Jun-2005


Page: 1 2

Related medicine news :

1. Nancy Brinker and Lance Armstrong honored with Centennial Medals at the AACR 2007 Annual Meeting
2. Cancer vaccine innovator honored with prestigious Florey Medal
3. ASTRO announces 2006 Gold Medal winners
4. Bazan to receive ARVO Proctor Medal
5. Ronald Breslow to receive 2006 Othmer Gold Medal
6. Sabin Gold Medal awarded to vaccine developer Dr. Albert Z. Kapikian

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rice bioengineer wins ASME Van Mow Medal

(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: